Chief Scientific Officer, POINT Biopharma
| Role | Organisation | Sources |
|---|---|---|
| Founder | Exiqon A/S | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
| Chief Scientific Officer (former) · Founder | Santaris Pharma A/S | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
| Chief Scientific Officer (former) | PNA Diagnostics A/S | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
| Chief Scientific Officer | POINT Biopharma | Brandon BioCatalyst portfolio |
| Chief Scientific Officer | CiVi Biopharma Inc | Brandon Capital portfolio |
| Amaroq Therapeutics | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming Dr Henrik Ørum. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Cancer biotech Amaroq Therapeutics appointed four experts to its advisory board as it moves toward clinical trials; the New Zealand company's backers include Brandon Capital, which reports $14m invested to date.
New Zealand biotech Amaroq Therapeutics reported early progress toward clinical trials and appointed four leading scientists to its scientific advisory board, strengthening its lncRNA cancer therapy programme.